Objectives To evaluate the efficacy and safety of combination chemotherapy with S-1 and oxaliplatin ( L-OHP) in patients with advanced biliary tract cancer( BTC) .Methods Twenty-six patients with advanced BTC were eligible.The chemother-apy regimen consisted of S-1(40mg/m2 p.o,bid,d1~14) and L-OHP (130mg/m2,d1),repeated every 3 weeks,A maximum of 6 treatment cycles were given.Results 26 patients were assessed for efficacy and safety.Of all patients,Com-plete response was ob-served in one patient ( 3.85%) , partial response in 9 ( 30.77%) , stable disease in 11 ( 42.31%) , progressive disease in 5 (23.08%),the overall response rate was 34.62% and the disease control rate was 80.77%.With a median follow-up of 16 months,the median progression-free survival (PFS) and overall survival (OS) were 8.6 months (95% CI 7.1~10.1) and 12.2 months (95%CI 9.4~15.0),respectively.The most common toxicities were leukopenia,anorexia,nausea/vomiting and peripheral sensory neuropathy,mostly one or two degree,and were tolerated.There were no treatment-related deaths.Conclusions Combina-tion chemo-therapy with S-1 and L-OHP was an effective and well tolerated first line regimen for advanced BTC.%目的：探讨替吉奥联合奥沙利铂一线治疗晚期胆道系统肿瘤（ BTC）的疗效和安全性。方法26例晚期胆道系统恶性肿瘤患者采用替吉奥联合奥沙利铂化疗方案，替吉奥40mg／m2，早晚2次口服，第1～14天，奥沙利铂130mg／m2，第1天，每21天为1个周期，共6个周期。结果26例患者均可评价疗效与安全性，其中完全缓解1例（3．85％），部分缓解9例（30．77％），病情稳定11例（42．31％），疾病进展5例（23．08％），总有效率34．62％，肿瘤控制率80．77％。中位无进展生存和总生存分别为8．6个月（95％CI：7．1～10．1个月）和12．2个月（95％CI：9．4～15．0个月）。主要毒副作是白细胞下降、厌食、恶心和呕吐及外周神经毒性，多为Ⅰ～Ⅱ度，均可耐受，无治疗相关性死亡。结论替吉奥联合奥沙利铂治疗晚期胆系恶性肿瘤疗效显著，具有较好的耐受性，有可能成为晚期胆道系统恶性肿瘤的一线化疗方案。
展开▼
